Coronary/Structural Heart

Boston Scientific victory upheld for stent

Shared by Ken Dropiewski on

More in Coronary/Structural Heart:

Share this story

The Federal court upheld a previous coronary stent win over Dr. David Jang

Appeals court upholds Boston Scientific win over stent pioneer Jang

BY , MassDevice

A federal appeals court today upheld a Boston Scientific (NYSE:BSX) win over coronary stent pioneer Dr. David Jang.

The case dates back to 1999, when Jang won approval from the U.S. Patent & Trademark Office for a stent design featuring lateral struts. In 2002, Jang inked a deal worth up to $160 million to license the patents to Marlborough, Mass.-based Boston Scientific; Jang received $50 million up front, according to court documents, but only $10 million of the remaining $110 million in milestone payments…

Read story at MassDevice

Ken has been in the cardiac, vascular, and interventional space for over 20 years. He is a Partner with McDermott + Bull Executive Search, recognized by Forbes as one of the industry's best with offices across North America and in Europe. Ken is hired by innovative cardiovascular device and biotech companies to help build their best teams possible at the executive level. Prior to search, Ken had an award winning commercial career at Boston Scientific and Johnson & Johnson to include such prestigious awards as President's Club, Ring Club, and Grand Awards. dropiewski@mbexec.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*